Home / Companies / Aquestive Therapeutics, Inc. / 11 Jun 2025
Aquestive Therapeutics, Inc.: meeting of 11 Jun 2025
Votes reported on Form N-PX, item by item
146 Form N-PX filers reported votes at the Aquestive Therapeutics, Inc. meeting of 11 Jun 2025. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
2 nominees; 69.5% of reported votes for; 17 filers withheld from or voted against at least one nominee.
178 vote records from 48 filers. 14 of the 47 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
204 vote records from 145 filers. 59 of the 136 filers that marked the item either way voted against management. 9 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
89 vote records from 48 filers. 0 of the 47 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | For | For |
| BlackRock and iShares | For | For | For |
| Fidelity | For | For | For |
| State Street and SPDR | For | For | For |
| American Century | No report | Against * | No report |
| Invesco | No report | Against * | No report |
| Equitable | For | For | For |
| Charles Schwab | For | For | For |
| Nuveen and TIAA | For | For | For |
| ProShares and ProFunds | Abstain or withhold * | Against * | For |
| John Hancock and Manulife | Abstain or withhold * | Against * | For |
| Morgan Stanley, Eaton Vance and Calvert | Abstain or withhold * | Against * | For |
| J.P. Morgan | No report | For | No report |
| Goldman Sachs | For | Against * | For |
| PGIM and Prudential | No report | For | No report |
| Northern Trust and FlexShares | Split or no vote | Against * | For |
| SEI | For | For | For |
| T. Rowe Price | For | Against * | For |
| Lincoln Financial | For | For | For |
| Voya | Split or no vote | Against * | For |
| Russell Investments | No report | For | No report |
| Nationwide | For | For | For |
| Victory Capital | Abstain or withhold * | Against * | For |
| Brighthouse Funds | Abstain or withhold * | Against * | For |
| Guggenheim and Rydex | Abstain or withhold * | Against * | For |
| Columbia Threadneedle | For | Against * | For |
| BNY Mellon | No report | For | No report |
| Principal | No report | Against * | No report |
| Pacific Life funds | For | For | For |
| Global X | For | For | For |
| AllianceBernstein | No report | Against * | No report |
| DWS | Abstain or withhold * | Against * | For |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Aquestive Therapeutics, Inc. meeting?
146 Form N-PX filers reported votes at the meeting of 11 Jun 2025. On say-on-pay, 59 of 136 voted against management (43.4%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Aquestive Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Aquestive Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Aquestive Therapeutics, Inc. with a meeting date within three days of 11 Jun 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.